Menu Search
Equities

Synairgen PLC

OMY:FRA

Synairgen PLC

Actions
  • Price (EUR)0.068
  • Today's Change0.012 / 20.35%
  • Shares traded6.00k
  • 1 Year change-2.86%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 08:22 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. The Company has developed and is testing an inhaled formulation of IFN-B designed to directly target the lungs, the primary site of many viral lung infections, including COVID-19.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-6.92m
  • Incorporated2004
  • Employees36.00
  • Location
    Synairgen PLCSouthampton General Hosp, Tremona RoadSOUTHAMPTON SO16 6YDUnited KingdomGBR
  • Phone+44 238 051 2800
  • Fax+44 238 051 2800
  • Websitehttps://www.synairgen.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.